Gilead's clinical research VP moves to U.S.-China NASH startup Terns Pharma
Gilead's vice president of clinical research, Erin Quirk, M.D., is joining the NASH and cancer-focused Terns Pharmaceuticals as its new chief medical officer.
The Shanghai and San Mateo, California-based company raised $80 million last October to support its early-stage pipeline, including three NASH programs from Eli Lilly & Co. It aims to begin clinical trials this year.
“Erin is a highly accomplished clinician with an extensive track record in developing and registering new trea...